Terumo Blood and Cell Technologies

What’s Your Superpower? We’ve had the privilege to meet and support incredible sickle cell disease (SCD) warriors. Their resilience and strength inspire us every day. With the launch of Netflix’s "Supacell," which creatively highlights a real disease people live with every day and features our very own Spectra Optia Apheresis System, we want to celebrate our real-life heroes even more. We invite all SCD patients, families, patient associations, and healthcare professionals to share their stories with us. How have you demonstrated superhuman strength and resilience in the face of SCD? Let’s amplify these inspiring stories together! Join us in recognizing our heroes and celebrating the blend of real-life resilience and superhero storytelling that "Supacell" brings to the world. Share your superpower story today and check out Supacell on Netflix! *The views of Supacell do not necessarily reflect the views or positions of Terumo Blood and Cell Technologies.* https://lnkd.in/g7vpRxKx Spectra Optia is either a registered trademark or trademark of Terumo BCT, Inc. in the United States and/or other countries. See https://lnkd.in/gUtxJYaV for details. #SCDWarriors #SickleCellDisease #SuperheroesAmongUs #ShareYourStory #Supacell #BlackHealthMatters #HealthcareInnovation

Acompáñenos en el XXI Congreso de la Asociación Mexicana de Medicina Transfusional. Esperamos contar con su presencia en el simposio "Eficiencia Impulsada por la Conectividad" en Expo Guadalajara, el viernes 20 de septiembre, de 15:00 a 17:00 h. Escuche a los expertos mientras exploran el futuro de la medicina transfusional junto con el poder de la conectividad. No se pierda esta oportunidad para que juntos aprovechemos al máximo el potencial de los datos. https://bit.ly/3B6AQLe #AMMTAC2024 #SolucionesParaBancosDeSangre #Hematología #Hemoterapia #TerapiaCelular

At Terumo Blood and Cell Technologies, we’re committed to more than just providing apheresis technology—we’re focused on expanding access to treatment options for more patients. We are proud to share that our research, “ASFA 2023 Guidelines-Based Usage of TPE in the Real-World in APAC: A Pilot/Exploratory Scoping Literature Review” was presented today at the 18th Congress of The World Apheresis Association (WAA) at Yogyakarta. Therapeutic Plasma Exchange (TPE), a common and effective apheresis procedure, helps remove harmful pathogens and antibodies from the blood. Our abstract evaluates the hypothesis that the real-world application of TPE across the Asia Pacific region (APAC) does not fully align with the latest ASFA 2023 guidelines and investigates variations in TPE usage. APAC is considered one region – but the healthcare system and patient population are diverse. TPE is considered an affordable treatment option for healthcare systems with resource limitations and we should not undermine its value. Some key takeaways are: ✔️ Few studies from APAC cite ASFA 2023, though when cited, it’s as an optimal treatment strategy. Actual usage remains unknown. Most publications are from India. 2023 is the year with the most publications. ✔️ ASFA 2019 is still routinely cited in articles published in year 2023/2024, despite the release of ASFA 2023. The lack of ASFA referencing doesn’t necessarily mean a lack of TPE procedures. As a global leader in apheresis technology, we are committed to identifying gaps and promoting best practices to ensure patients everywhere have access to the care they need. Read the abstract poster here👉 https://bit.ly/3zsBuCl #Apheresis #TherapeuticApheresis #TherapeuticPlasmaExchange #TPE #TerumoProud

Congress season is in full swing around the world 🌏🌍🌏 Meet our team from the Asia Pacific at the 18th Congress of The World Apheresis Association (WAA) in Yogyakarta. We are proud sponsors of WAA and our associates are busily involved in many engaging programmes. Thanks to everyone who joined our hands-on Spectra Optia Apheresis System workshop and the lunch symposium by Dr. Anton Alexander on apheresis procedures in pediatric care. We will be at WAA until September 13. Come visit our booth and #connect with us, as we continue to engage and share best practices with key industry stakeholders on advancing apheresis care. https://lnkd.in/gry7RbbM #TerumoConnect #WAA2024 #Apheresis #TherapeuticApheresis

This week, our Latin America team hosted a successful Distributor Sales Meeting in Buenos Aires, Argentina. We were delighted to welcome 12 distributors from South and Central America. It was an enriching opportunity to share insights, strengthen partnerships, and explore new opportunities together. A highlight of the event was our visit to the Garrahan Regional Hemotherapy Center, a model of excellence with its 100% voluntary donation system. Their dedication to community-driven care is truly inspiring. Thank you to all the participants who made this event a success. Your energy and commitment help us continue to unlock the potential of blood and cells.

Terumo Blood and Cell Technologies is proud to have supported the parliamentary roundtable chaired by Baroness Ritchie of Downpatrick: “Unlocking Cell and Gene Therapies: Addressing Apheresis Capacity in the UK.” The roundtable focused on the need to increase apheresis capacity in order to support the development of Advanced Therapeutic Medicinal Products (ATMPs) in the UK. It is clear that, to address this need, industry, government, the NHS and patients should work collaboratively to develop a holistic system thinking approach to removing hurdles in the ATMP supply chain. As new therapies emerge for conditions with larger patient populations, strengthening the manufacturing supply chain is essential to meet the rising demand. During the roundtable, we heard from: Baroness Ritchie of Downpatrick, member of House of Lords Henny Braund MBE, CEO of Anthony Nolan Robert Cross, CAR-T therapy recipient Hugo Fabre, Ph.D, Head of Medical Affairs EMEA at Terumo BCT Jacqueline Barry, Chief Clinical Officer at Catapult James Griffin, Clinical Director of Therapeutic Apheresis at NHS Blood and Transplant Helen Keane, Apheresis Lead at University College London Hospitals We appreciate the valuable insights shared during the roundtable and remain dedicated to collaborating with various stakeholders to enhance patient access to innovative therapies. Terumo BCT is committed to supporting the NHS in addressing the key challenges within the cell and gene therapy supply chain. #TerumoBCT #terumobloodandcelltechnologies #cellapheresis #ukparliament

📢 Terumo Blood and Cell Technologies partners with UK’s Anthony Nolan to help shape the future of cell collections We proudly announce our new partnership with Anthony Nolan, a leading UK stem cell charity, to open its new Cell Collection Centre in Nottingham, UK. Our Spectra Optia™ Apheresis Systems will support life-changing stem cell collections that help patients with blood cancers and other disorders while advancing cell and gene therapy research. Antoinette Gawin, Terumo BCT President and CEO, says, "Patients and donors are at the heart of this growing field of healthcare, and their experience, access and outcomes need to remain the focus." Spectra Optia is used in over 67% of white blood cell collections worldwide, and we’re committed to leveraging our extensive data and technology to optimize each donation and quality of cells collected. Anthony Nolan's new centre, supported by nearly one million potential donors on its register, will accelerate patient treatment and enhance the donor experience, addressing the increasing global demand for cell collection. Learn more about this new collaboration and Anthony Nolan’s future work in cell and gene therapy: https://lnkd.in/gpcrcFWW #TerumoBCT #CellTherapy #AnthonyNolan #SpectraOptia #HealthcareInnovation

In CAR T-cell immunotherapy, a patient’s T cells are extracted, genetically engineered and multiplied, and then infused back to the patient’s body. The first CAR T-cell immunotherapy was first approved by the FDA in 2017 and is used today to treat cancers such as lymphoma. But the research for utilizing this technology doesn’t stop there. Currently, scientists and drug developers are exploring ways to treat other medical conditions such as autoimmune diseases. Mindy Miller, PhD, Manager Senior Scientist and Stuart Gibb, Ph.D, Head of Scientific Strategy share their insights on developing and manufacturing cell and gene-based therapies for non-oncological indications. “If you think about the needs, it could be extreme,” Dr. Miller comments. Although blood cancer affects about 200,000 patients per year in the US, “there are 25 to 50 million patients with autoimmune diseases.” Dr. Gibb adds that because the technology is still in an early phase, there is lot to consider as these therapies are commercialized. “Shortening the manufacturing cycle is a hot topic for all device manufacturers,” but, “manufacturing is one part of a more complex puzzle.” Read more here: Peering into the future of CAR-T cell therapies https://bit.ly/3MDSjNF #CART #CellTherapies #immunotherapy

Spectra Optia Apheresis System: Starring in "Supacell" – Netflix’s New Hit Show! We’re excited about the Netflix series Supacell. Why? Because our Spectra Optia Apheresis System makes a cameo appearance, but more importantly because this groundbreaking series is building awareness for sickle cell disease (SCD) and the health struggles of those dealing with this blood-based illness. "Supacell" is set in South London and follows five regular people with working class lives and relationships who suddenly gain superpowers due to their sickle cells transforming into “supacells”. This series intertwines fiction with the real challenges and triumphs associated with SCD, offering a powerful social commentary on its impact within the black community. Supacell hit Netflix #1 in June 2024 and, in mid-August, Netflix announced season 2! ICYMI enjoying summer outdoor activities, tune in to "Supacell" for an engaging, thought-provoking experience that entertains and educates about SCD. We’re proud to see our technology playing a crucial role in this narrative. Let’s celebrate this powerful story together! *The views of Supacell do not necessarily reflect the views or positions of Terumo Blood and Cell Technologies.* https://lnkd.in/gW3Sdtms Spectra Optia is either a registered trademark or trademark of Terumo BCT, Inc. in the United States and/or other countries. See https://lnkd.in/gUtxJYaV for details. #Supacell #NetflixSeries #SickleCellAwareness #BlackHealthMatters #HealthcareInnovation

Antje Kremer met Candelaria Iglesias after joining an insightful session at #ISCTEurope2024: “Is our infrastructure ready for the future of ATMP Development?” 🚀 During the discussion, experts shed light on the current infrastructure supporting ATMP development and manufacturing across Europe and the UK. 🏥🌍 It’s clear that collaboration between key players—academia, industry, and regulators—will be pivotal in advancing these groundbreaking cell therapies. The goal? To bring transformative treatments to patients and change the course of diseases that were once thought untreatable. 💡💪 The future of ATMPs is bright, and for us from Terumo Blood and Cell Technologies it’s energizing to be part of this journey. 🌟 👉 Get in touch with us to learn how we’re advancing cell therapy solutions: https://lnkd.in/gZHbec2A #ATMP #CellTherapy #HealthcareInnovation #Collaboration #FutureOfMedicine